Advertisement

Rheumaderm pp 279-283 | Cite as

Enalapril (10 Mg/Day) in Systemic Sclerosis

One Year, Double Blind, Randomised Study (ESS-1): Echocardiographic Substudy—Three Months Follow-Up
  • Andrej Biłan
  • M. Chibowska
  • B. Makaruk
  • R. Palusiriski
  • J. Węglarz
  • S. Ostrowski
  • A. Witczak
  • J. Hanzlik
  • D. Krasowska
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)

Abstract

The ESS-1 study was designed to evaluate the long-term effects of the angiotensin converting enzyme inhibitor(ACEI) enalapril (10mg per day) on the cardio-pulmonary system in patients with scleroderma (SSc). We estimated changes in heart diameters, systolic and diastolic left ventricle function and mean values of pulmonary artery pressure after 3 months treatment. The study group comprise 41 patients with SSc. 18 patients received placebo and 23 ones were given enalapril. After 3 months of treatment we did not observe statistically significant differences in heart diameters and left ventricle systolic function parameters between treated group and placebo. Enalapril therapy did not affect left ventricle diastolic function, nevertheless differences in MVA were almost of statistical significance. Echocardiographic signs of pulmonary hypertension were found in 4 patients.

Keywords

Pulmonary Hypertension Mitral Regurgitation Angiotensin Converting Enzyme Inhibitor Systemic Sclerosis Pulmonary Artery Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Follansbee WP, Miller TR, Curtiss EI: A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J. Rheumatol. 17: 656–661 (1990).PubMedGoogle Scholar
  2. 2.
    Valentini G, Maione S: Cardiopathy in systemic sclerosis. Recenti Progressi in Medicina. 87: 557–63 (1996)PubMedGoogle Scholar
  3. 3.
    Kucharz EJ: Cardiac involvement in patients with systemic sclerosis. Pol Arch Med Wewn. 97: 1–4 (1997).PubMedGoogle Scholar
  4. 4.
    Gaasch WH: Diagnosis and Treatment of Heart Failure Based on Left Ventricular Systolic or Diastolic Dysfunction [Clinical Cardiology] J.Am. Med. Ass. 271: 1276–1280 (1994).CrossRefGoogle Scholar
  5. 5.
    Zawada ET Jr, Clements PJ, Furst DA, Bloomer HA, Paulus HE, Maxwell MH. Clinical course of patients with scleroderma renal crisis treated with captopril. Nephron. 27, 74–8 (1981).PubMedCrossRefGoogle Scholar
  6. 6.
    Armstrong GP, Whalley GA, Doughty RN, Gamble GD, Flett SM, Tan PL, Sharpe DN: Left ventricular function in scleroderma. Br J Rheumatol. 35: 983–8 (1996).PubMedCrossRefGoogle Scholar
  7. 7.
    Dubecq S, Constans J, Roudaut R et al.: Cardiac involvements in scleroderma: study with echocardiography and cardiac Doppler in 38 patients. Rev de Med Int 14: 937–941 (1993).CrossRefGoogle Scholar
  8. 8.
    Murata I, Takenaka K, Yoshinoya S, Kikuchi K, Kiuchi T, Tanigawa T, Ito K: Clinical evaluation of pulmonary hypertension in systemic sclerosis and related disorders. A Doppler echocardiographic study of 135 Japanese patients. Chest. 111: 36–43 (1997).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Andrej Biłan
    • 1
  • M. Chibowska
    • 2
  • B. Makaruk
    • 1
  • R. Palusiriski
    • 1
  • J. Węglarz
    • 1
  • S. Ostrowski
    • 1
  • A. Witczak
    • 1
  • J. Hanzlik
    • 1
  • D. Krasowska
    • 2
  1. 1.I Department of Internal MedicineUniversity School of MedicineLublinPoland
  2. 2.Department of DermatologyUniversity School of MedicineLublinPoland

Personalised recommendations